الاتحاد الأوروبي - الكرواتية - EMA (European Medicines Agency)

zoetis belgium sa - oclacitinib maleata - agenti za dermatitis, isključujući kortikosteroide - psi - - treatment of pruritus associated with allergic dermatitis in dogs. - treatment of clinical manifestations of atopic dermatitis in dogs.

الجبل الأسود - الكرواتية - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - tofacitinib - film tableta - 10mg

الجبل الأسود - الكرواتية - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - tofacitinib - film tableta - 5mg

الجبل الأسود - الكرواتية - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - tofacitinib - tableta sa produženim oslobađanjem - 11mg

الاتحاد الأوروبي - الكرواتية - EMA (European Medicines Agency)

pfizer europe ma eeig - Тофацитиниб - artritis, reumatoidni - imunosupresivi - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 i 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

البوسنة والهرسك - الكرواتية - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

pfizer bh d.o.o. sarajevo - тофацитиниб - filmom obložena tableta - 5 mg/1 tableta - 1 filmom obložena tableta sadrži: 5 mg tofacitiniba (u obliku tofacitinib citrata)

البوسنة والهرسك - الكرواتية - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

pfizer bh d.o.o. sarajevo - тофацитиниб - filmom obložena tableta - 10 mg/1 tableta - 1 filmom obložena tableta sadrži: 10 mg tofacitiniba (u obliku tofacitinib citrata)

الاتحاد الأوروبي - الكرواتية - EMA (European Medicines Agency)

gilead sciences ireland uc, galapagos nv - filgotinib maleate - artritis, reumatoidni - imunosupresivi - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

الاتحاد الأوروبي - الكرواتية - EMA (European Medicines Agency)

pfizer limited - Тофацитиниб - artritis, reumatoidni - imunosupresivi - liječenje reumatoidnog artritisa.

كرواتيا - الكرواتية - HALMED (Agencija za lijekove i medicinske proizvode)

pfizer croatia d.o.o., slavonska avenija 6, zagreb - flukonazol - kapsula, tvrda - 150 mg - urbroj: jedna tvrda kapsula sadrži 150 mg flukonazola